Glucagon-like peptide-1 (GLP-1) is an incretin hormone primarily secreted by enteroendocrine L-cells in the small intestine in response to nutrient intake. It enhances glucose-dependent insulin secretion, inhibits glucagon release, slows gastric emptying, and promotes satiety, making it central to glucose metabolism and energy balance. “Total GLP-1” refers to the measurement of both active and inactive forms of the hormone in plasma or serum, offering a comprehensive view of GLP-1 secretion regardless of its rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). Unlike assays that measure only active GLP-1, total GLP-1 quantification provides a more stable and reliable index of L-cell secretory activity.
In clinical and research settings, total GLP-1 serves as a useful biomarker in the study and management of metabolic diseases such as type 2 diabetes and obesity. It is used to evaluate the efficacy of GLP-1 receptor agonists and DPP-4 inhibitors, monitor postprandial hormonal responses, and investigate gut hormone dynamics in bariatric surgery patients. In research, total GLP-1 measurements help elucidate the role of the gut-brain axis, investigate nutrient-induced hormonal changes, and explore novel therapeutic targets for metabolic and gastrointestinal disorders. Its broad physiological relevance and stability in measurement make total GLP-1 a valuable tool in metabolic and endocrine research.
This product is manufactured in USA by Eagle Biosciences.
| Size | 1 x 96 Well |
| Sensitivity | 0.1 pM |
| Dynamic Range | 2 -54 pmol/L |
| Incubation Time | overnight |
| Sample Type | Plasma |
| Storage | 2-8°C |
| Alternative Names | Glucagon Like Peptide, Incretin Hormone, Enteroglucagon |